Jordan Axelrad

The pathogenesis of inflammatory bowel disease (IBD) involves crosstalk between genetic and microbial factors that influence immune reactions. Tofacitinib, a pan JAK-STAT inhibitor, is a small molecule indicated for the treatment of moderate-to-severe ulcerative colitis (UC)…

SOCIETY: AGA

BACKGROUND AND AIMS: A treat-to-target (TTT) strategy of striving for symptomatic and endoscopic remission is recommended for the management of inflammatory bowel diseases (IBD). Yet, real-world uptake of TTT strategies has been modest…

Background: Patients with inflammatory bowel disease (IBD) often modify their diet in attempt to manage their disease and symptoms. In some cases, dietary changes involve excessive restriction, which may place patients at risk for adverse consequences…

Join us as we dive deep into rapid multi-pathogen diagnostic testing. We'll discuss use cases, how to interpret syndromic testing data, and how this data can positively impact clinical decision making. Learn how syndromic testing can do more, faster…

BACKGROUND: Despite increasing therapeutic options in the treatment of ulcerative colitis (UC), achieving disease remission remains a major clinical challenge. Nonresponse to therapy is common and clinicians have little guidance in selecting the optimal therapy for an individual patient…

INTRODUCTION: Recent guidelines propose a fecal calprotectin (FCP) monitoring strategy in the year after Crohn’s disease (CD) resection for low-risk individuals or those receiving pharmacologic prophylaxis to prevent postoperative recurrence (POR)…

SOCIETY: AGA While it is intuitive that inflammation of the bowel can be affected positively and negatively by diet, it is only recently that the underpinnings of diet on inflammatory bowel disease have been explored…

This session will explore the therapeutic potential of the gut microbiome in treating inflammatory bowel disease and gastrointestinal cancers…